Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10385678 | 0.80 | TDP1 (0.39) | TDP1 | |
| SCHEMBL10385183 | 0.78 | TDP1 (0.41) | TDP1 | |
| SCHEMBL9567014 | 0.76 | LMNA (0.31) | — | |
| SCHEMBL2475309 | 0.76 | — | — | |
| SCHEMBL26626969 | 0.76 | TDP1 (0.38) | TDP1 | |
| SCHEMBL1701174 | 0.76 | TAAR1 (0.34) | TDP1 | |
| SCHEMBL27363044 | 0.76 | TDP1 (0.40) | TDP1 | |
| SCHEMBL10385681 | 0.74 | TDP1 (0.35) | TDP1 | |
| SCHEMBL62392 | 0.74 | CA1 (0.35) | TDP1 | |
| SCHEMBL2057256 | 0.73 | TDP1 (0.36) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763709-A | Preparation method of coliform group detection reagent by enzyme substrate method | 浙江泰林生命科学有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111763709-A | Preparation method of coliform group detection reagent by enzyme substrate method | 浙江泰林生命科学有限公司 | 2020-10-13 | — | — | CN | disclosed |
| EP-1149899-B9 | Culture medium for avian totipotential embryonic cells | AGRONOMIQUE INST NAT RECH (FR) | 2011-09-21 | — | — | EP | disclosed |
| EP-1149899-B1 | Culture medium for avian totipotential embryonic cells | AGRONOMIQUE INST NAT RECH (FR) | 2011-02-23 | — | — | EP | disclosed |
| EP-1148122-B1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR | KYOWA HAKKO BIO CO LTD (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090148916-A1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-7470528-B2 | DNA encoding hydroxylase | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20080261273-A1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1146126-B1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITORS | KYOWA HAKKO KOGYO KK (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060154348-A1 | Process for producing HMG-CoA reductase inhibitors | KYOWA HAKKO KOGYO CO. LTD (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1148122-A1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-10-24 | — | — | EP | disclosed |
| EP-1146126-A1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-6300329-B1 | HETEROCYCLIC PYRIDO(1,2-A)PYRAZINE COMPOUNDS FOR TREATMENT OF PARKINSON'S DISEASE | PFIZER PRODUCTS INC. | 2001-10-09 | — | — | US | disclosed |
| EP-1115402-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS | Pfizer Products Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| EP-1003739-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000016777-A1 | PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PARKINSON'S DISEASE, ADHD AND MICROADENOMAS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0953567-A2 | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity | Pfizer Products Inc. (US) | 1999-11-03 | — | — | EP | disclosed |
| WO-1999009025-A2 | 2-(4-ARYL OR HETEROARYL-PIPERAZIN-1-YLMETHYL)-1H-INDOLE DERIVATIVES INTERACTING WITH THE DOPAMINE D4 RECEPTOR | PFIZER PRODUCTS INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| EP-0787180-A1 | ACTIVE RETINOIC ACID FREE CULTURE MEDIUM FOR AVIAN TOTIPOTENTIAL EMBRYONIC CELLS | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) (FR) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012793-A1 | ACTIVE RETINOIC ACID FREE CULTURE MEDIUM FOR AVIAN TOTIPOTENTIAL EMBRYONIC CELLS | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (FR) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148916-A1 | PROCESS FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR | COASY, HMGCR, BLVRB | TDP1 1620/4885 |
| US-20060154348-A1 | Process for producing HMG-CoA reductase inhibitors | COASY, HMGCR, BLVRB | TDP1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.